- Advertisement -
Proteomics International managing director Dr Richard Lipscombe said: “The new CMS pricing determination and PLA code for PromarkerD are pivotal to our next phase of commercialisation in the United States. This will drive adoption, patient access, and commercial partnerships in the United…
Click here to view the original article.
